B-CELL LEUKEMIA
Clinical trials for B-CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …
Matched conditions: B-CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC
-
Engineered immune cells take on tough leukemia
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy for people with B-cell leukemia that does not have the CD19 protein, often because it stopped responding to earlier CAR T treatment. The modified immune cells target six different markers on leukemia cells. The trial aims to see i…
Matched conditions: B-CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…
Matched conditions: B-CELL LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…
Matched conditions: B-CELL LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC